After years of consumers tracking health metrics without clear guidance on how to use them, NeuroRester Corp. has unveiled its vision for the next generation of wearable wellness technology. The company today announced the launch of Wearable 2.0, anchored by its flagship devices, NeuroRester and CardioGyms. At the center of this ecosystem is the proprietary NAP (Nightly-Active Protocol), a system developed to transform wearable technology from a passive data-collection tool into an active wellness support platform.

The rise of the "Quantified Self" movement introduced consumers to smartwatches, rings, and other devices capable of measuring metrics such as Heart Rate Variability (HRV), sleep quality, and recovery scores. While these devices provide valuable insights, they often leave users wondering how to translate data into meaningful action. Wearable 2.0 seeks to address this challenge by offering personalized guidance based on the information users already collect.

Moving Beyond Observation
According to NeuroRester Corp., traditional wearable technology has largely focused on monitoring and reporting health information without offering direct support for wellness improvement. Wearable 2.0 introduces a different approach by integrating intelligent data processing and personalized recommendations.
 

NAP: Personalized Wellness Support
Serving as the foundation of the ecosystem, NAP (Nightly-Active Protocol) connects existing wearable devices—including Apple Watch, Oura, and WH—with NeuroRester's hardware solutions. Once users define their wellness goals and preferences within the app, the protocol automatically schedules customized wellness sessions designed to encourage consistent relaxation and recovery habits that fit naturally into daily life.

The Device Ecosystem
NeuroRester
A compact earbud-style device that incorporates Bioboosti technology to help users relax and support a greater sense of calm.

CardioGyms
A flexible wearable that can be worn on the wrist, calf, or integrated into specialized socks, offering comfort throughout the day while supporting relaxation-focused wellness routines.
"People are no longer satisfied with simply receiving reports that indicate poor sleep or low recovery," said NeuroRester Corp.'s Founder and CEO. "They want practical ways to improve how they feel. Wearable 2.0 and NAP help convert health data into simple, personalized wellness actions, shifting the conversation from understanding the numbers to taking meaningful steps based on them."

Availability
Early Access enrollment will begin in mid-June and will be limited to the first 1,000 participants, who will receive special introductory pricing. Broader product availability is planned for July 2026 through NeuroRester's official website.

About NeuroRester Corp.
Headquartered in Campbell, California, NeuroRester Corp. is advancing the Wearable 2.0 category through the development of proprietary wellness technologies. Its innovations, including NAP and Bioboosti, are designed to support natural relaxation, recovery, and overall well-being.

Important Information
Statements regarding these products have not been reviewed by the U.S. Food and Drug Administration. NeuroRester and CardioGyms are intended for wellness purposes only and are not designed to diagnose, treat, cure, or prevent any disease or medical condition. Descriptions of expected wellness benefits are based on product design objectives and user experience goals; outcomes have not been clinically validated and may differ among individuals.

To deliver personalized wellness experiences, NeuroRester Corp. utilizes health information collected from compatible wearable devices.

Can advanced mathematical models help detect heart disease before symptoms even appear? Increasingly, the answer is yes. By analyzing data collected during routine medical visits, these models can uncover early warning signs that might otherwise go unnoticed.

“We now have advanced AI tools that allow us to gather and analyze enormous volumes of medical data in ways that weren’t possible before,” explained Nina Goodheart, Senior Vice President and President of the Structural Heart and Aortic division at Medtronic. “Artificial intelligence helps us detect specific heart conditions earlier and enables faster, personalized treatment.”

Take aortic stenosis (AS) as an example—a serious heart valve condition affecting roughly 250,000 Americans each year. In AS, the aortic valve narrows, reducing blood flow from the heart to the body. The symptoms often develop gradually and vary between individuals, making it difficult to diagnose early.

However, every time you visit a doctor, a trail of health data is recorded in your Electronic Health Record (EHR). This data may include lifestyle factors, test results, physician notes, and more. Hidden within that information could be signs of a developing heart issue like AS—but finding them manually is like searching for a needle in a haystack.

That’s where artificial intelligence becomes vital.

“AI helps bring structure to overwhelming and complex health data,” said Chris Rogers, Senior Director of Strategic Provider Solutions at Tempus AI, a Chicago-based company that uses data science to enhance medical diagnostics. “Our algorithms are designed to detect subtle patterns that may not be visible to clinicians reviewing patient records individually.”

Tempus Next, the company’s AI-powered software, uses around 60 advanced algorithms to identify gaps in care for 15 different cardiovascular diseases, including AS. “Medical data is incredibly nuanced,” Rogers noted. “Our technology is built to adapt to the unique context of each healthcare provider, offering insights that are both specific and actionable.”

The software scans your EHR—including physician notes—and matches your health data to established diagnostic criteria for AS. If your data meets enough indicators, the system alerts your healthcare provider, potentially prompting further evaluation or treatment.

This isn’t just a concept—it’s already delivering results.

In a recent collaboration with the John Brancaccio St. Francis Hospital and Heart Center in New York, Tempus Next identified 388 patients who met criteria for AS or another serious heart condition but weren’t yet receiving appropriate treatment. These findings were flagged for doctors, offering a chance for earlier intervention.

Now, Medtronic and Tempus are expanding their work through a new clinical trial called ALERT, which will review patient records from six additional healthcare sites. The study aims to identify not only patients who are being overlooked but also the systemic reasons behind delayed diagnoses—ultimately helping to design better care processes.

“The underdiagnosis of severe aortic stenosis is a widespread issue that can be deadly within two years if untreated,” said Dr. Wayne Batchelor, Interventional Cardiologist and Chair of the ALERT study’s steering committee. “Our goal is to create more timely, equitable treatment pathways and break down the barriers preventing proper care.”

The potential impact of this technology is enormous.

“It’s inspiring to think about what’s possible,” Goodheart said. “We could one day apply this to millions of patients, catching AS before it becomes critical and improving or extending countless lives. The numbers speak for themselves.”

And that’s one kind of math that could truly save lives.